目的 研究脑血管病患者急性期 ( 10 d内 )及亚急性期 ( 4周内 )血浆低分子量肝素 ( L MWH)浓度 ,了解 L MWH样物质水平的自然变化趋势 ,并观察 L MMH治疗干预后体内 L MWH血浓度的变化以及出血副反应与浓度之间的关系。方法 应用发色...目的 研究脑血管病患者急性期 ( 10 d内 )及亚急性期 ( 4周内 )血浆低分子量肝素 ( L MWH)浓度 ,了解 L MWH样物质水平的自然变化趋势 ,并观察 L MMH治疗干预后体内 L MWH血浓度的变化以及出血副反应与浓度之间的关系。方法 应用发色底物法抗 FXa测定法对 84例急性脑血管病患者的血浆 L MWH浓度进行动态观察。结果 脑梗死患者与脑出血患者血浆 L MWH浓度在 0 .3～ 0 .4之间 ,相比无显著性差异 ;应用 L MWH治疗的脑梗死患者血浆 L MWH浓度高于非治疗组 ,且有显著差异性 ;血浆 L MWH浓度与出血副反应有一定的相关性。结论 监测血浆 L MWH浓度有益于防止出血副反应 ,为个体化给药提供了基础。展开更多
A multiplexed targeted proteomic assay using a mTRAQ-MRM/MS-based approach was developed and assessed to systematically quantify the relative expressions of five candidate plasma apolipoproteins that have been previou...A multiplexed targeted proteomic assay using a mTRAQ-MRM/MS-based approach was developed and assessed to systematically quantify the relative expressions of five candidate plasma apolipoproteins that have been previously shown to be dysregulated in neuropsychiatric disorders and cognitive dysfunction:apolipoprotein H(APOH),apolipoprotein J(APOJ),apolipoprotein A4(APOA4),apolipoprotein E(APOE),and apolipoprotein D(APOD).The peptides and transitions of each APO were carefully selected according to the tandem MS signals acquired on a TripleTOFTM 5600,followed by optimization of the declustering potential and collision energy voltages for transitions on a QTRAP 5500.Our results showed that the collision energies of mTRAQ-labeled peptides were approximately 15%–20%higher than corresponding non-labeled peptides.Through optimized transitions and parameters,we analyzed the relative abundances of the five APOs in human plasma with and without depletion of high abundant proteins.The results indicated that the MRM signals of four target APOs were significantly increased after depletion,while the MRM signal of one APO,APOD,was decreased.Furthermore,the relative abundances of the five target APOs in healthy human plasma were stable,and the ranking of these proteins according to their MS responses changed slightly.Therefore,we deduced that the rank order of the MS signals for these target proteins can be developed as a diagnostic signature for diseased plasma.展开更多
文摘目的 研究脑血管病患者急性期 ( 10 d内 )及亚急性期 ( 4周内 )血浆低分子量肝素 ( L MWH)浓度 ,了解 L MWH样物质水平的自然变化趋势 ,并观察 L MMH治疗干预后体内 L MWH血浓度的变化以及出血副反应与浓度之间的关系。方法 应用发色底物法抗 FXa测定法对 84例急性脑血管病患者的血浆 L MWH浓度进行动态观察。结果 脑梗死患者与脑出血患者血浆 L MWH浓度在 0 .3～ 0 .4之间 ,相比无显著性差异 ;应用 L MWH治疗的脑梗死患者血浆 L MWH浓度高于非治疗组 ,且有显著差异性 ;血浆 L MWH浓度与出血副反应有一定的相关性。结论 监测血浆 L MWH浓度有益于防止出血副反应 ,为个体化给药提供了基础。
基金supported by the National Basic Research Program of China(2009CB918300)the National Natural Science Foundation of China(31271189 and 81101009)
文摘A multiplexed targeted proteomic assay using a mTRAQ-MRM/MS-based approach was developed and assessed to systematically quantify the relative expressions of five candidate plasma apolipoproteins that have been previously shown to be dysregulated in neuropsychiatric disorders and cognitive dysfunction:apolipoprotein H(APOH),apolipoprotein J(APOJ),apolipoprotein A4(APOA4),apolipoprotein E(APOE),and apolipoprotein D(APOD).The peptides and transitions of each APO were carefully selected according to the tandem MS signals acquired on a TripleTOFTM 5600,followed by optimization of the declustering potential and collision energy voltages for transitions on a QTRAP 5500.Our results showed that the collision energies of mTRAQ-labeled peptides were approximately 15%–20%higher than corresponding non-labeled peptides.Through optimized transitions and parameters,we analyzed the relative abundances of the five APOs in human plasma with and without depletion of high abundant proteins.The results indicated that the MRM signals of four target APOs were significantly increased after depletion,while the MRM signal of one APO,APOD,was decreased.Furthermore,the relative abundances of the five target APOs in healthy human plasma were stable,and the ranking of these proteins according to their MS responses changed slightly.Therefore,we deduced that the rank order of the MS signals for these target proteins can be developed as a diagnostic signature for diseased plasma.
